Free Trial

Kiora Pharmaceuticals (KPRX) Competitors

Kiora Pharmaceuticals logo
$2.86 +0.00 (+0.14%)
Closing price 07/3/2025 01:00 PM Eastern
Extended Trading
$2.88 +0.02 (+0.70%)
As of 07/3/2025 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KPRX vs. ARTV, CLNN, KPTI, ATHE, ACRV, VOR, EGRX, AKTX, ELYM, and ESLA

Should you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Artiva Biotherapeutics (ARTV), Clene (CLNN), Karyopharm Therapeutics (KPTI), Alterity Therapeutics (ATHE), Acrivon Therapeutics (ACRV), Vor Biopharma (VOR), Eagle Pharmaceuticals (EGRX), Akari Therapeutics (AKTX), Eliem Therapeutics (ELYM), and Estrella Immunopharma (ESLA). These companies are all part of the "pharmaceutical products" industry.

Kiora Pharmaceuticals vs. Its Competitors

Artiva Biotherapeutics (NASDAQ:ARTV) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

Kiora Pharmaceuticals has higher revenue and earnings than Artiva Biotherapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Artiva Biotherapeutics$250K160.29-$65.37MN/AN/A
Kiora Pharmaceuticals$16.02M0.54$3.60M-$2.90-0.99

Artiva Biotherapeutics currently has a consensus target price of $17.80, suggesting a potential upside of 982.07%. Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 249.16%. Given Artiva Biotherapeutics' higher probable upside, equities analysts clearly believe Artiva Biotherapeutics is more favorable than Kiora Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artiva Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Kiora Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Kiora Pharmaceuticals' return on equity of -42.82% beat Artiva Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Artiva BiotherapeuticsN/A -75.95% -39.51%
Kiora Pharmaceuticals N/A -42.82%-32.18%

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Artiva Biotherapeutics had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 1 mentions for Artiva Biotherapeutics and 0 mentions for Kiora Pharmaceuticals. Artiva Biotherapeutics' average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Artiva Biotherapeutics Neutral
Kiora Pharmaceuticals Neutral

Summary

Artiva Biotherapeutics and Kiora Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

Get Kiora Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KPRX vs. The Competition

MetricKiora PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$8.68M$2.43B$5.56B$9.04B
Dividend YieldN/A1.78%5.24%4.01%
P/E Ratio-0.999.2227.6420.24
Price / Sales0.54680.34416.55117.31
Price / Cash2.30158.5936.8958.10
Price / Book0.334.588.035.67
Net Income$3.60M$31.34M$3.18B$249.21M
7 Day Performance-1.24%3.25%2.93%3.28%
1 Month Performance-7.01%3.46%1.72%3.95%
1 Year Performance-37.60%0.77%34.39%20.98%

Kiora Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KPRX
Kiora Pharmaceuticals
2.3167 of 5 stars
$2.86
+0.1%
$10.00
+249.2%
-37.6%$8.68M$16.02M-0.9910
ARTV
Artiva Biotherapeutics
2.2284 of 5 stars
$1.62
+2.5%
$17.80
+998.8%
N/A$38.49M$250K0.0081Gap Up
High Trading Volume
CLNN
Clene
2.8042 of 5 stars
$4.10
-4.2%
$40.00
+875.6%
-43.6%$38.45M$340K-1.01100News Coverage
KPTI
Karyopharm Therapeutics
3.8397 of 5 stars
$4.33
-1.1%
$43.20
+897.7%
-62.4%$37.84M$145.24M-0.33380
ATHE
Alterity Therapeutics
2.6351 of 5 stars
$4.37
+4.0%
$12.00
+174.6%
+120.8%$37.24MN/A0.0010Gap Down
ACRV
Acrivon Therapeutics
2.6119 of 5 stars
$1.18
flat
$17.71
+1,401.2%
-81.7%$37MN/A-0.5358
VOR
Vor Biopharma
3.9828 of 5 stars
$0.29
+20.7%
$7.06
+2,333.5%
+107.6%$36.24MN/A-0.18140Analyst Revision
Gap Up
High Trading Volume
EGRX
Eagle Pharmaceuticals
N/A$2.79
-3.0%
N/A-45.5%$36.23M$257.55M0.00100Gap Down
AKTX
Akari Therapeutics
1.533 of 5 stars
$1.16
+3.6%
N/A-58.9%$36.04MN/A0.009
ELYM
Eliem Therapeutics
N/A$1.21
-1.6%
N/A-80.7%$36MN/A-2.289
ESLA
Estrella Immunopharma
2.2244 of 5 stars
$0.92
-7.1%
$16.00
+1,639.1%
-23.6%$35.80MN/A-3.54N/AGap Up

Related Companies and Tools


This page (NASDAQ:KPRX) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners